Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
- 1 February 2012
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 20 (3), 1271-1280
- https://doi.org/10.1016/j.bmc.2011.12.021
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- 9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase InhibitorsJournal of Medicinal Chemistry, 2011
- Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- Synthesis and Structure−Affinity Relationships of Novel Dibenzylideneacetone Derivatives as Probes for β-Amyloid PlaquesJournal of Medicinal Chemistry, 2011
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapyExpert Review of Anticancer Therapy, 2009
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 casesBlood, 2003
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994
- Synthesis of a model for the BCE ring system of bruceantin. A caveat on the cyclohexene .fwdarw. trans diaxial diol conversionThe Journal of Organic Chemistry, 1980